This inventor holds 1 USPTO granted patent. Top assignee: The Medicines Company (Leipzig) Gmbh. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: The Innovations of Daniel Dönnecke
Introduction
Daniel Dönnecke is a notable inventor based in Weimar, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of coagulation factor Xa inhibitors. His work is crucial for advancing therapies for cardiovascular diseases and thromboembolic events.
Latest Patents
Dönnecke holds a patent for "Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof." This invention relates to novel base-substituted benzylamine analogs of general formula (I), wherein A represents P-P with P⟷(A) and P⟷(B). These analogs are designed for use as coagulation factor Xa inhibitors, which play a vital role in the therapy and prophylaxis of cardiovascular diseases and thromboembolic events. He has 1 patent to his name.
Career Highlights
Daniel Dönnecke is currently employed at The Medicines Company (Leipzig) GmbH, where he continues to innovate in the pharmaceutical sector. His work focuses on developing new therapeutic agents that can significantly improve patient outcomes.
Collaborations
Dönnecke collaborates with esteemed colleagues such as Jörg Stürzebecher and Andrea Schweinitz. Their combined expertise enhances the research and development efforts at their company.
Conclusion
Daniel Dönnecke's contributions to the field of pharmaceuticals, particularly through his innovative patent, highlight his role as a key inventor in the industry. His work continues to pave the way for advancements in medical therapies.